Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results.

Harvey Jones has something to celebrate after a positive set of results boosted the GSK share price after a disappointing run. Is there scope for more growth? The content of this article is ...

GSK Plc (NYSE:GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

The user of the website is referred to as "you" and "your". By posting on our share chat boards you are agreeing to the following: If you are going to post non-English, please also post an English ...

GSK's oncology sales increased 98% in 2024, and reflects strong demand and potentially new launches or indications for cancer therapies.

Yet GSK is clearly healing from its multiple comorbidities — the worst of which was the (now largely resolved) legal overhang related to heartburn medicine Zantac. Chief executive Emma Walmsley also ...

British pharmaceutical giant GSK plc (NYSE:GSK) saw its share prices on Wednesday rise by 8.21 percent to finish at $37.70 apiece as investor optimism was fueled by a more positive outlook for ...

The GSK (LSE: GSK) share price was causing me a lot of aggro – until Wednesday (5 February). Suddenly it was top of the FTSE 100 leaderboard after jumping 7.61% in just a day! I bought the ...

Mark Hartley weighs up the growing potential in GSK as its share price makes rare gains following a promising set of results. When investing, your capital is at risk. The value of your ...

By posting on our share chat boards you are agreeing to the ... The investors are seeking a jury trial and damages against GSK for violating federal securities laws. The class action is open ...